News

Dana-Farber/Boston Children's again ranked among the top national pediatric cancer programs

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #3 in the nation in its new 2018-19 Best Children's Hospitals report.

Pioneering hematologist to receive 2018 Nemmers Prize in Medical Science

Stuart H. Orkin, MD, an investigator of the Howard Hughes Medical Institute at Boston Children’s Hospital and Dana-Farber Cancer Institute and professor at Harvard Medical School known for his landmark discoveries into blood cell development and the genetic basis of blood disorders, is the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University.

Dana-Farber/Boston Children’s researcher is part of a new Stand Up To Cancer campaign with Marvel Studios’ Avengers and American Airlines

Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.

Bursting with gene therapies and other innovative treatments, the overall survival rate for our blood and marrow transplant patients is exceeding expectations

Dana-Farber/Boston Children's is the only pediatric stem cell transplant center in the U.S. to exceed expected outcomes for allogeneic transplant patients in 2017.

A new gene therapy transplantation technique could improve treatment of neurodegenerative disease

Alessandra Biffi, MD, led a study that shows the efficacy of a new gene therapy transplantation technique that could have future applications for treating neurodegenerative diseases.

New gene therapy clinical trial offers hope for sickle cell disease

David Williams, MD, discusses Dana-Farber/Boston Children's new gene therapy clinical trial for sickle cell disease in a live webchat.

Two Dana-Farber/Boston Children's faculty members elected to National Academy of Medicine

Two Dana-Farber/Boston Children's Cancer and Blood Disorders Center faculty members, Scott Allen Armstrong, MD, PhD, and Scott Pomeroy, MD, PhD, have been elected to the National Academy of Medicine (NAM).

The space between heartache and happiness: Two sons with adrenoleukodystrophy and a gene therapy clinical trial

For the Rojas family, a clinical trial of gene therapy for adrenoleukodystrophy has meant both happiness and heartache.

Gene therapy halts progression of cerebral adrenoleukodystrophy in clinical trial

The devastating neurodegenerative disease typically affects young boys and causes death within 10 years

Dana-Farber/Boston Children's responds to FDA approval of CAR-T cell therapy

The FDA's approval of CAR-T therapy for refractory pediatric and young adult ALL underscores the potential of CAR T-cell therapies, a form of cancer immunotherapy, to treat a wide range of cancers, researchers say.